DNA X

Q2 FY2026 EarningsSONM.US Q2 FY26 results significantly missed consensus as the company underwent a radical strategic pivot. Continuing operations reported zero revenue following the sale of its legacy handset business and the temporary shutdown of the newly acquired DNA X crypto platform for upgrades. While Net Income ($5.1M) was bolstered by a $15.3M asset sale gain, recurring metrics were weak: GAAP EPS of -$0.91 from continuing operations missed the $5.22 mean estimate, and operating cash flow was -$5.5M vs. the $3.8M expected. Management expects a relaunch in Q4 FY26, supported by $5M in subsequent preferred stock funding.